HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
The increasing prevalence of obesity has contributed to the rise of non-alcoholic fatty liver disease & liver health concerns worldwide. NAFLD occurs when excess fat accumulates in the liver, leading to inflammation and potential progression to non-alcoholic steatohepatitis (NASH), cirrhosis, or liver failure. Insulin resistance, metabolic syndrome, and dyslipidemia are key factors driving fat deposition in hepatocytes. Beyond liver damage, NAFLD is strongly associated with an elevated risk of cardiovascular disease. Lifestyle interventions, including dietary modifications, exercise, and weight loss, remain the primary treatment strategies. Emerging pharmacological therapies targeting liver fat metabolism and inflammation are being developed to provide more effective interventions for managing obesity-related liver disease.
